Subclinical Hypothyroidism | Thyroid Hormone Replacement for Subclinical Hypothyroidism
Subclinical Hypothyroidism research study
What is the primary objective of this study?
Subclinical hypothyroidism (SCH) is a common condition among older men and women. Although by definition SCH comprises biochemically mild thyroid hormone deficiency without overt symptoms, it is a possible contributor to multiple problems in older age. Thyroid hormone has effects on numerous physiological systems, including the vascular tree, heart, skeletal muscle and brain. Therefore, thyroxine substitution to overcome thyroid hormone deficiency has the potential to give multisystem benefits to older people with SCH. Small studies have reported reduced atherosclerosis and improved heart function with thyroxine replacement, but no large clinical trials have been performed. Therefore the available evidence is limited, leading to major variations in guidelines and clinical practice, with uncertainty regarding the indications for screening and treatment. The investigators propose a multicentre randomised placebo controlled trial to assess the impact of thyroxine replacement in a minimum of 540 older adults (maximum 750) with persisting SCH (excluding those in whom it is a temporary phenomenon who are unlikely to benefit). The investigators will include older men and women with a wide age range and of varying health status. Outcomes include health related quality of life, muscle strength, executive cognitive function and cardiovascular events, with a minimum of 1 year of follow up. Blood and urine samples will be stored in a biobank, to allow future research on causes of ill health in older people with SCH. The investigators have the support of patient advocacy groups and a consortium with the wide range of expertise and experience required to conduct large scale multicentre clinical trials. The proposal explores the multisystem and quality of life benefits to older people of a tailored approach to management of SCH. This clinical trial should definitively clarify whether thyroxine treatment for SCH provides benefits that are relevant for patients. This trial will provide strong evidence with the potential to improve clinical practice, reduce health care costs and promote healthy ageing of older adults.
Who is eligible to participate?
Inclusion Criteria: - Community-dwelling patients aged >=65 years with Subclinical Hypothyroidism (SCH). SCH is defined as elevated TSH levels (>=4.6, <=19.9 mU/L) and free thyroxine (fT4) in reference range measured on a minimum of two occasions at least 3 months apart. Exclusion Criteria: - Subjects currently on Levothyroxine or antithyroid drugs, amiodarone or lithium. - Recent thyroid surgery or radio-iodine (within 12 months). - Grade IV NYHA heart failure. - Prior clinical diagnosis of dementia. - Recent hospitalisation for major illness or elective surgery (within 4 weeks). - Recent acute coronary syndrome, including myocardial infarction or unstable angina (within 4 weeks). - Terminal illness. - Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. - Subjects who are participating in ongoing RCTs of therapeutic interventions (including CTIMPs) - Plan to move out of the region in which the trial is being conducted within the next 2 years (proposed minimum follow-up period).
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:LevothyroxineThe intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
LevothyroxineOral Levothyroxine, starting dose 25 or 50 micrograms increased to a maximum of 150 micrograms once daily.
Start Date: May 2014
Completed Date: November 18, 2016
Phase: Phase 4
Primary Outcome: Thyroid-specific quality of life - Hypothyroid symptoms and Fatigue symptoms (co-primary outcomes)
Secondary Outcome: Health-related quality of life
Study sponsors, principal investigator, and references
Principal Investigator: David J Stott, MBChB MD
Lead Sponsor: NHS Greater Glasgow and Clyde
Collaborator: University of Glasgow